Physician profile
Brian E Mcgeeney
NPI 1043272198
$11,546.43
in general payments reported to CMS, 2019-2025
12 companies · $4,158 in 2025
The $4,158 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $2,766 · 2024: $4,395 · 2025: $4,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,100 · Honoraria: $4,050 · Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,100.00 |
| Honoraria | $4,050.00 |
| Food and Beverage | $402.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $4,157.81 | 2025 | Symbravo |
| Upsher-Smith Laboratories LLC | $2,765.79 | 2020 | |
| Abbvie INC. | $2,459.64 | 2024 | |
| Lundbeck LLC | $1,935.44 | 2024 | Vyepti |
| Lilly USA, LLC | $54.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $45.39 | 2019 | |
| Genzyme Corporation | $39.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.83 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.64 | 2019 | |
| Allergan, INC. | $14.41 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.55 | 2019 | |
| Promius Pharma LLC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mcgeeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.